ArticleHormones & cancer2017

A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor κB Pathways with Hybrid Drugs for Breast Cancer Therapy.

Irida Kastrati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.